Blue Cross Blue Shield RI Cochlear Implants Coverage

Coverage Criteria for Cochlear Implants

Bilateral or Unilateral Cochlear Implantation (General Medical Necessity)

Covered when ALL of the following are met (Medicare Advantage and Commercial criteria vary):

Age: Medicare: no age specified; Commercial: age 9 months or older for standard implants; hybrid implants: age 18+ for initial FDA indication (expanded approvals noted)

Hearing loss severity: Medicare: bilateral moderate to profound sensorineural hearing loss; Commercial: bilateral severe to profound sensorineural hearing loss (adults) as defined by device labeling

Limited benefit from hearing aids: Documented limited or no benefit from appropriately fit bilateral hearing aids using open-set sentence recognition or developmental criteria (Medicare: ≤60% best-aided sentence recognition on recorded tests; Commercial adults: ≤50% correct in the ear to be implanted; children: failure to develop basic auditory skills or ≤30% for older children)

Cognitive and surgical suitability: Individual should have cognitive ability to use auditory clues, willingness to undergo extended rehabilitation, freedom from active middle ear infection, an accessible cochlear lumen suitable for implantation, absence of lesions of the auditory nerve/central auditory pathway, and no contraindications to surgery

Device labeling: Use must be consistent with Food and Drug Administration (FDA)-approved labeling for the device

Hybrid Cochlear Implant/Acoustic Hearing Aid Systems

Covered when ALL of the following are met:

Age: Initial FDA approval: age 18 years and older; later expanded approvals may change age eligibility—document device-specific labeling

Audiometric criteria: Residual low-frequency hearing with severe-to-profound high-frequency sensorineural hearing loss; follow device-specific audiometric thresholds and word recognition criteria per FDA labeling (examples: low-frequency thresholds no poorer than 60 dB HL up to 500 Hz; 2000–4000 Hz average ≥75 dB HL in ear to be implanted; CNC word recognition 10–60% in ear to be implanted)

Limited benefit from appropriately fit bilateral hearing aids: Documented limited benefit from hearing aids despite appropriate fitting as defined by device labeling and standard testing

Unilateral Hearing Loss / Single-Sided Deafness

Coverage stance differs by product:

Medicare Advantage: May be covered when performed in FDA-approved category B investigational device exemption clinical trials or as a routine cost in clinical trials as described by CMS

Commercial Products: Considered not medically necessary for unilateral hearing loss (single-sided deafness) with or without tinnitus due to insufficient evidence to determine effects on health outcomes

Evidence summary and coverage implication

Coverage stance and clinical evidence summary

Evidence for unilateral hearing loss/SSD: Available evidence for cochlear implants in unilateral sensorineural hearing loss (SSD/AHL) includes small feasibility studies, small RCTs, and observational studies that report improvements in sound perception, localization, and patient-reported outcomes but are limited by small sample sizes, heterogeneity in protocols, and inconsistent binaural/localization results; overall evidence is insufficient to conclude improvement in net health outcome for unilateral hearing loss.

Clinical trials and ongoing postmarketing studies may further elucidate outcomes

Requests to upgrade an existing, functioning external cochlear implant system solely for aesthetic improvement or convenience—for example, switching to smaller-profile components or changing from a body-worn processor to a behind-the-ear (BTE) model—are not covered. Replacement of internal or external components only to obtain advanced or next‑generation technology is also not covered. Replacement is considered medically necessary only when the component(s) no longer function or cannot be repaired, or when inadequate response to the existing component(s) substantially interferes with activities of daily living.

The evidence evaluating cochlear implantation for unilateral sensorineural hearing loss (single-sided deafness or asymmetric hearing loss) includes small open-label randomized trials, feasibility studies, and observational series. Studies report improvements in sound perception, localization, and quality of life in some patients, but results are limited by small sample sizes, heterogeneous evaluation protocols, inconsistent binaural localization outcomes, and lack of longer-term prospective comparisons to best-aided hearing beyond 6 months. Ongoing post‑marketing studies may provide additional data, but current evidence is insufficient to conclude that cochlear implantation produces a net health benefit for unilateral hearing loss.

For Commercial products, cochlear implantation to treat unilateral hearing loss (single-sided deafness), with or without tinnitus, is considered not medically necessary because the evidence is insufficient to demonstrate improved health outcomes. Medicare Advantage policy may differ and follows CMS guidance; therefore coverage for unilateral implantation under Medicare Advantage may be handled separately in accordance with CMS determinations and applicable clinical trial categories.

Coding and Billing Codes

Referenced related codes (diagnostic imaging, lab, machine tests, and therapeutic services like auditory rehabilitation)mixed

No codes listed

Covered CPT Codes (surgery)CPTCovered

69930

Cochlear device implantation, with or without mastoidectomy

Covered CPT Codes (speech therapy)CPTCovered

92626	Evaluation of auditory rehabilitation status; first hour
92627	Evaluation of auditory rehabilitation status; each additional 15 minutes
92630	Auditory rehabilitation; pre-lingual hearing loss
92633	Auditory rehabilitation; post-lingual hearing loss

Covered CPT Codes (diagnostic/programmings)CPTCovered

92601	Diagnostic analysis of cochlear implant, patient younger than 7 years of age; with programming
92602	Diagnostic analysis of cochlear implant, patient younger than 7 years of age; subsequent reprogramming
92603	Diagnostic analysis of cochlear implant, age 7 years or older; with programming
92604	Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming

Covered HCPCS L86xx Codes (prosthetic devices / DME)HCPCSCovered

L8614	Cochlear device, includes all internal and external components
L8615	Headset/headpiece for use with cochlear implant device, replacement
L8616	Microphone for use with cochlear implant device, replacement
L8617	Transmitting coil for use with cochlear implant device, replacement
L8618	Transmitter cable for use with cochlear implant device or auditory osseointegrated device, replacement
L8619	Cochlear implant, external speech processor and controller, integrated system, replacement
L8621	Zinc air battery for use with cochlear implant device and auditory osseointegrated sound processors, replacement, each
L8622	Alkaline battery for use with cochlear implant device, any size, replacement, each
L8627	Cochlear implant, external speech processor, component, replacement
L8628	Cochlear implant, external controller component, replacement

1–10 of 14

1/2

Hybrid device audiometric thresholds and scores — examples and numeric thresholds

Low-frequency hearing threshold (example)No poorer than 60 dB HL up to and including 500 Hz

High-frequency threshold (ear to be implanted)Average of 2000, 3000, and 4000 Hz ≥ 75 dB HL

Contralateral ear mid–high frequency thresholdAverage of 2000, 3000, and 4000 Hz ≥ 60 dB HL (moderately severe to profound)

Preoperative CNC word recognition (ear to be implanted)CNC word recognition score between 10% and 60% inclusively in the preoperative aided condition

Contralateral ear word recognition limitContralateral ear equal to or better than implanted ear but not more than 80% correct

Provider Actions, Documentation & Billing

Prior Authorization

Prior authorization is not required.

Billing Rule

Coverage and billing benefit assignment

Cochlear implantation (CPT 69930) and associated services are billed to the appropriate member benefit according to the service type. The surgical procedure 69930 is covered under the member's surgery services benefit. Speech therapy codes (e.g., 92626, 92627, 92630, 92633) are covered under the member's speech therapy benefit. Diagnostic analysis and programming codes (e.g., 92601–92604) are covered under diagnostic imaging/lab/machine tests. Prosthetic and external device HCPCS (L8614–L8629, L8621–L8625) are covered under the prosthetic devices or durable medical equipment benefit as indicated. Providers must bill each service to the benefit category that corresponds to the code.

Surgery benefit: 69930

Background

Cochlear implants are electronic prosthetic devices that electrically stimulate the auditory nerve to restore sound awareness and support communication in individuals with moderate‑to‑profound sensorineural hearing loss who derive limited benefit from hearing aids. Devices consist of internal components (implanted receiver and electrode array) and external components (microphone, sound processor, transmitter). Successful outcomes typically require postoperative auditory rehabilitation and appropriate candidacy assessment including audiometric testing, demonstration of limited benefit from amplification, and surgical and cognitive suitability.

Definitions

Cochlear implant — definition of device and components

DefinitionAn electronic prosthetic system with internal (implanted receiver and electrode array) and external (microphone, sound processor, transmitter) components that provides direct electrical stimulation to the auditory nerve, bypassing nonfunctional cochlear hair cells.

Internal componentsImplanted receiver implanted within the temporal bone and an electrode array that extends into the cochlea

External componentsMicrophone, external sound processor, and external transmitter that capture and code sound for transmission to the internal receiver

Limited benefit from amplification — Medicare and Commercial thresholds

Medicare threshold (adults)Limited benefit defined as ≤60% correct in the best-aided listening condition on recorded open-set sentence recognition tests

Commercial adults threshold

Revision History & References

Reference
1. Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) 50.3, https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=245&ncdver=3&bc=0.
2. Cochlear Implants in Adults and Children. NIH Consensus Statement Online. 1995;13(2):1-30.
3. Bond M, Mealing S, Anderson R, et al. The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Health Technol Assist. Sep 2009;13(44):1-330. PMID 19799825.
4. Gaylor JM, Raman G, Chung M, et al. Cochlear implantation in adults: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. Mar 2013;139(3):265-72. PMID 23429927.
5. McRackan TR, Bauschard M, Hatch JL, et al. Meta-analysis of quality-of-life improvement after cochlear implantation and associations with speech recognition abilities. Laryngoscope. Apr 2018;128(4):982-990. PMID 28731538.
6. McRackan TR, Bauschard M, Hatch JL, et al. Meta-analysis of Cochlear Implantation Outcomes Evaluated With General Health-related Patient-reported Outcome Measures. Otol Neurotol. Jan 2018;39(1):29-36. PMID 29227446.
7. Crathorne L, Bond M, Cooper C, et al. A systematic review of the effectiveness and cost-effectiveness of bilateral multichannel cochlear implants in adults with severe-to-profound hearing loss. Clin Otolaryngol. Oct 2012;37(5):342-54. PMID 22928754.
8. Choi JS, Betz J, Li L, et al. Association of Using Hearing Aids or Cochlear Implants With Changes in Depressive Symptoms in Older Adults. JAMA Otolaryngol Head Neck Surg. Jul 2016;142(7):652-7. PMID 27258813.
9. van Zon A, Smulders YE, Ramakers GG, et al. Effect of unilateral and simultaneous bilateral cochlear implantation on tinnitus: A Prospective Study. Laryngoscope. Apr 2016;126(4):956-61. PMID 26255618.
10. Bond M, Elston J, Mealing S, et al. Effectiveness of multi-channel unilateral cochlear implants for profoundly deaf children: a systematic review. Clin Otolaryngol. Jun 2009;34(3):199-211. PMID 19531168.
11. Baron S, Blanchard M, Parodi M, et al. Sequential bilateral cochlear implants in children and adolescents: Outcomes and prognostic factors. Eur Ann Otorhinolaryngol Head Neck Dis. Apr 2019;136(2):69-73. PMID 30314876.
12. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Nucleus 24 Cochlear Implant System (P970051/S172). 2020; https://www.accessdata.fda.gov/cdrh_docs/pdf/P970051S172B.pdf. Accessed January 2, 2022.
13. Lyu J, Kong Y, Xu TQ, et al. Long-term follow-up of auditory performance and speech perception and effects of age on cochlear implantation in children with pre-lingual deafness. Chin Med J (Engl). Aug 20 2019;132(16):1925-1934. PMID 31365431.
14. Karltorp E, Eklof M, Ostlund E, et al. Cochlear implants before 9 months of age led to more natural spoken language development without increased surgical risks. Acta Paediatr. Feb 2020;109(2):332-341. PMID 31350923.
15. Sharma A, Dorman MF. Central auditory development in children with cochlear implants: clinical implications. Adv Otorhinolaryngol. 2006;64:66-88. PMID 16891837.
16. Forli F, Arslan E, Bellelli S, et al. Systematic review of the literature on the clinical effectiveness of the cochlear implant procedure in paediatric patients. Acta Otorhinolaryngol Ital. Oct 2011;31(5):281-98. PMID 22287820.
17. Sterkers F, Merklen F, Piron JP, et al. Outcomes after cochlear reimplantation in children. Int J Pediatr Otorhinolaryngol. Jun 2015;79(6):840-843. PMID 25843784.
18. Black J, Hickson L, Black B, et al. Prognostic indicators in paediatric cochlear implant surgery: a systematic literature review. Cochlear Implants Int. May 2011;12(2):67-93. PMID 21756501.
19. Pakdaman MN, Herrmann BS, Curtin HD, et al. Cochlear implantation in children with anomalous cochleovestibular anatomy: a systematic review. Otolaryngol Head Neck Surg. Feb 2012;146(2):180-90. PMID 22140206.
20. Fernandes NF, Morettin M, Yamaguti EH, et al. Performance of hearing skills in children with auditory neuropathy spectrum disorder using cochlear implant: a systematic review. Braz J Otorhinolaryngol. Jan-Feb 2015;81(1):85-96. PMID 25458263.
21. Vlastarakos PV, Proikas K, Papacharalampous G, et al. Cochlear implantation under the first year of age-the outcomes. A critical systematic review and meta-analysis. Int J Pediatr Otorhinolaryngol. Feb 2010;74(2):119-26. PMID 19896223.
22. Ching TY, Dillon H, Day J, et al. Early language outcomes of children with cochlear implants: interim findings of the NAL study on longitudinal outcomes of children with hearing impairment. Cochlear Implants Int. 2009;10 Suppl 1:28-32. PMID 19067433.
23. Colletti L, Mandala M, Zoccante L, et al. Infants versus older children fitted with cochlear implants: performance over 10 years. Int J Pediatr Otorhinolaryngol. Apr 2011;75(4):504-9. PMID 21277638.
24. Guerzoni L, Murri A, Fabrizi E, et al. Social conversational skills development in early implanted children. Laryngoscope. Sep 2016;126(9):2098-105. PMID 26649815.
25. Lammers MJ, van der Heijden GJ, Pourier VE, et al. Bilateral cochlear implantation in children: a systematic review and best-evidence synthesis. Laryngoscope. Jul 2014;124(7):1694-9. PMID 24390811.
26. Broomfield SJ, Murphy J, Emmett S, et al. Results of a prospective surgical audit of bilateral paediatric cochlear implantation in the UK. Cochlear Implants Int. Nov 2013;14 Suppl 4:S19-21. PMID 24533758.
27. Sarant J, Harris D, Bennet L, et al. Bilateral versus unilateral cochlear implants in children: a study of spoken language outcomes. Ear Hear. Jul-Aug 2014;35(4):396-409. PMID 24557003.
28. Escorihuela Garcia V, Pitarch Ribas MI, Llopez Carratala I, et al. Comparative study between unilateral and bilateral cochlear implantation in children of 1 and 2 years of age. Acta Otorrinolaringol Esp. May-Jun 2016;67(3):148-55. PMID 26632253.
29. Friedmann DR, Green J, Fang Y, et al. Sequential bilateral cochlear implantation in the adolescent population. Laryngoscope. Aug 2015;125(8):1952-8. PMID 25946489.
30. Illg A, Giourgas A, Kral A, et al. Speech comprehension in children and adolescents after sequential bilateral cochlear implantation with long interimplant interval. Otol Neurotol. Jun 2013;34(4):682-9. PMID 23640090.
31. van Zon A, Peters JP, Stegeman I, et al. Cochlear implantation for patients with single-sided deafness or asymmetrical hearing loss: a systematic review of the evidence. Otol Neurotol. Feb 2015;36(2):209-19. PMID 25502451.
32. Benchetrit L, Ronner EA, Anne S, et al. Cochlear Implantation in Children With Single-Sided Deafness: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. Jan 2021;147(1):58-69. PMID 33151295.
33. Marx M, Mosnier I, Venail F, et al. Cochlear Implantation and Other Treatments in Single-Sided Deafness and Asymmetric Hearing Loss: Results of a National Multicenter Study Including a Randomized Controlled Trial. Audiol Neurootol. 2021;26(6):414-424. PMID 33789270.
34. Peters JPM, van Heteren JAA, Wendrich AW, et al. Short-term outcomes of cochlear implantation for single-sided deafness compared to bone conduction devices and contralateral routing of sound hearing aids—Results of a Randomised controlled trial (CINGLE-trial). PLoS One. 2021;16(10):e0257447. PMID 34644322.
35. Buss E, Dillon MT, Rooth MA, et al. Effects of Cochlear Implantation on Binaural Hearing in Adults With Unilateral Hearing Loss. Trends Hear. 2018;22:2331216518771173. PMID 29732951.
36. Dillon MT, Buss E, O'Connell BP, et al. Low-Frequency Hearing Preservation With Long Electrode Arrays: Inclusion of Unaided Hearing Threshold Assessment in the Postoperative Test Battery. Am J Audiol. Mar 2020;29(1):1-5. PMID 31835906.
37. Galvin JJ, Fu QJ, Wilkinson EP, et al. Benefits of Cochlear Implantation for Single-Sided Deafness: Data From the House Clinic-University of Southern California-University of California, Los Angeles Clinical Trial. Ear Hear. Jul/Aug 2019;40(4):766-781. PMID 30358655.
38. Peter N, Kleinjung T, Probst R, et al. Cochlear implants in single-sided deafness - clinical results of a Swiss multicentre study. Swiss Med Wkly. Dec 2019;149:w20171. PMID 31880806.
39. Poncet-Wallet C, Mamelle E, Godey B, et al. Prospective Multicentric Follow-up Study of Cochlear Implantation in Adults With Single-Sided Deafness: Tinnitus and Audiological Outcomes. Otol Neurotol. Dec 20 2019. PMID 31868784.
40. Dillon MT, Buss E, Rooth MA, et al. Cochlear Implantation in Cases of Asymmetric Hearing Loss: Subjective Benefit, Word Recognition, and Spatial Hearing. Trends Hear. 2020;24:2331216520945524. PMID 32808881.
41. Food and Drug Administration. Post-Approval Studies (PAS): MED-EL New Enrollment SSD/AHL Study. 2020; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm?t_id=647845&c_id=5585. Accessed January 4, 2022.
42. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): MED-EL Cochlear Implant System (P000025/S104). 2019; https://www.accessdata.fda.gov/cdrh_docs/pdf/P000025S104B.pdf. Accessed January 16, 2021.
43. Mertens G, De Bodt M, Van de Heyning P. Cochlear implantation as a long-term treatment for ipsilateral incapacitating tinnitus in subjects with unilateral hearing loss up to 10 years. Hear Res. Jan 2016;331:1-6. PMID 26433053.
44. Rahne T, Plontke SK. Functional Result After Cochlear Implantation in Children and Adults With Single-sided Deafness. Otol Neurotol. Oct 2016;37(9):e332-40. PMID 27631656.
45. Vlastarakos PV, Nazos K, Tavoulari EF, et al. Cochlear implantation for single-sided deafness: the outcomes. An evidence-based approach. Eur Arch Otorhinolaryngol. Aug 2014;271(8):2119-26. PMID 24096818.
46. Ramos Macias A, Falcon Gonzalez JC, Manrique M, et al. Cochlear implants as a treatment option for unilateral hearing loss, severe tinnitus and hyperacusis. Audiol Neurootol. 2015;20 Suppl 1:60-6. PMID 25997672.
47. Tavora-Vieira D, Marino R, Krishnaswamy J, et al. Cochlear implantation for unilateral deafness with and without tinnitus: a case series. Laryngoscope. May 2013;123(5):1251-5. PMID 23553411.
48. Pillsbury HC, Dillon MT, Buchman CA, et al. Multicenter US Clinical Trial With an Electric-Acoustic Stimulation (EAS) System in Adults: Final Outcomes. Otol Neurotol. Mar 2018;39(3):299-305. PMID 29342054.
49. Food and Drug Administration. Approval Letter: Nucleus Hybrid L24 Cochlear Implant System (P130016). 2014; https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130016a.pdf. Accessed January 5, 2022.
50. Roland JT, Gantz BJ, Waltzman SB, et al. United States multicenter clinical trial of the cochlear nucleus hybrid implant system. Laryngoscope. Jan 2016;126(1):175-81. PMID 26152811.
51. Roland JT, Gantz BJ, Waltzman SB, et al. Long-term outcomes of cochlear implantation in patients with high-frequency hearing loss. Laryngoscope. Aug 2018;128(8):1939-1945. PMID 29330858.
52. Lenarz T, James C, Cuda D, et al. European multi-centre study of the Nucleus Hybrid L24 cochlear implant. Int J Audiol. Dec 2013;52(12):838-48. PMID 23992489.
53. Santa Maria PL, Gluth MB, Yuan Y, et al. Hearing preservation surgery for cochlear implantation: a metaanalysis. Otol Neurotol. Dec 2014;35(10):e256-69. PMID 25233333.
54. Causon A, Verschuur C, Newman TA. A Retrospective Analysis of the Contribution of Reported Factors in Cochlear Implantation on Hearing Preservation Outcomes. Otol Neurotol. Aug 2015;36(7):1137-45. PMID 25853614.
55. Gantz BJ, Dunn C, Oleson J, et al. Multicenter clinical trial of the Nucleus Hybrid S8 cochlear implant: Final outcomes. Laryngoscope. Apr 2016;126(4):962-73. PMID 26756395.
56. American Academy of Otolaryngology -- Head and Neck Surgery. Position Statement: Cochlear Implants. November 10, 2020; http://www.entnet.org/Practice/policyCochlearImplants.cfm. Accessed January 7, 2022.
57. Raman G, Lee J, Chung MG, et al. Technology Assessment Report: Effectiveness of Cochlear Implants in Adults with Sensorineural Hearing Loss Rockville, MD: Agency for Healthcare Research and Quality; 2011.
58. National Institute for Health and Care Excellence (NICE). Cochlear Implants for Children and Adults With Severe to Profound Deafness [TA566]. 2019; https://www.nice.org.uk/guidance/ta566/. Accessed January 7, 2022.

OpenPayer

Cochlear Implants - Medical Coverage Policy